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A B S T R A C T
Oligodendrocytes are in contact with neurons, wrap axons with a myelin sheath that protects their structural
integrity, and facilitate nerve conduction. Oligodendrocytes also form a syncytium with astrocytes which in-
teracts with neurons, promoting reciprocal survival mediated by activity and by molecules involved in energy
metabolism and trophism. Therefore, oligodendrocytes are key elements in the normal functioning of the cen-
tral nervous system. Oligodendrocytes are affected following different insults to the central nervous system
including ischemia, traumatism, and inflammation. The term oligodendrogliopathy highlights the prominent
role of altered oligodendrocytes in the pathogenesis of certain neurological diseases, not only in demyelinat-
ing diseases and most leukodystrophies, but also in aging and age-related neurodegenerative diseases with ab-
normal protein aggregates. Most of these diseases are characterized by the presence of abnormal protein de
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posits, forming characteristic and specific inclusions in neurons and astrocytes but also in oligodendrocytes, thus
signaling their involvement in the disease. Emerging evidence suggests that such deposits in oligodendrocytes are
not mere bystanders but rather are associated with functional alterations. Moreover, operative modifications in
oligodendrocytes are also detected in the absence of oligodendroglial inclusions in certain diseases. The present
review focuses first on general aspects of oligodendrocytes and precursors, and their development and functions,
and then introduces and updates alterations and dysfunction of oligodendrocytes in selected neurodegenerative
diseases with abnormal protein aggregates such as multiple system atrophy, Lewy body diseases, tauopathies,
Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal lobar degeneration with TDP-43 inclusions
(TDP-43 proteinopathies), and Creutzfeldt-Jakob´s disease as a prototypical human prionopathy.
1. Oligodendrocytes: general aspects
In addition to neurons and astrocytes, other cells, smaller in size,
are present in the nervous system. These cells, called the “third ele-
ment” turned out to be two different cell types after pioneering stud-
ies by Del Rio-Hortega (1921); one of these was microglia, the other
oligodendroglia. The two cell types have different origins, morphology
and functions; processes in some subtypes of oligodendroglial cells run
in parallel to myelin thus suggesting a relationship between oligoden-
droglia and myelin (Penfield, 1924; Boullerne, 2016). Four different
types were described by Pio del Rio-Hortega as detailed in a recent re-
view (Perez-Cerda et al., 2015). Type I have small round cell bodies
and large numbers of very fine cellular processes associated with thin
myelinated fibers in the grey matter and interfascicular white matter;
Type II are cuboidal with few and thick processes which trap axons lon-
gitudinally in the white matter; Type III have one or two long cellular
processes and they are present in the brain stem and spinal cord; Type
IV have an elongated cell body and unique long processes running in
parallel to thick axons in the white matter of the brain stem and spinal
cord. Perineuronal oligodendroglial cells are called “perineuronal satel-
lites” whereas another subtype includes oligodendroglial cells localized
in the proximity of small blood vessels and are called, for this reason,
“perivascular satellites”. Functions of perivascular oligodendrocytes are
barely known although endothelial cell-oligodendrocyte interactions are
altered in small vessel disease and aging (Rajani and Williams, 2017).
Oligodendrocytes represent 75% of glial cells in the adult human brain
(Pelvig et al., 2008).
Substantial knowledge about oligodendroglia and myelin in the cen-
tral nervous system came out of electron microscopy observations and
made it clear that oligodendrocytes are the only cells producing myelin
in the central nervous system (Bunge, 1968; Raine, 1984; Hildebrand et
al., 1993). Individual axons are myelinated by consecutive oligodendro-
cytes arranged in line; eachsegment or internode is separated from the
next by a node of Ranvier. The myelin sheath is made up of thick mem-
brane bi-layers of about 12 nm in periodicity formed by alternating elec-
tron-dense (major dense line of myelin) and electron-light (intra-period
line of cytoplasm) tightly connected at their edges by thigh junctions
between the electron-dense layers (Baumann and Pham-Dinh, 2001;
Sherman and Brophy, 2005; Ozgen et al., 2016; Li and Richardson,
2016). This structure is not homogeneous along the internode but has
non-compact regions such as the outer and inner periaxonal lips, the
paranodal loops and interconnected cytoplasmic pockets (Pedraza et al.,
2001; Traka et al., 2002; Poliak and Peles, 2003; Möbius et al., 2008;
Hartline, 2008; De Monasterio-Schrader et al., 2012; Velumian et al.,
2011; Aggarwal et al., 2011a; Nave and Werner, 2014).
Myelin sheaths protect the axonal membrane, promote the spread
of electric signal along the axon, and decrease the capaci
tancy thus increasing the speed of the action potential with more effi-
ciency (Rosenbluth, 2009; Bakiri et al., 2011; Harris and Attwell, 2012;
Babbs and Shi, 2013). The nodes of Ranvier separate internodes. Axons
at the site of nodes are enriched in voltage-gated sodium channels and
potassium-gated channels Nav 1.6, Nav 1.1, KCNQ2/3, Kv 3.1, Kv1.1/
1.2; and postsynaptic density protein 93/95 (PSD 93/95) which are all
crucial for saltatory nerve conduction. In addition, cytoskeletal scaffold-
ing proteins ankyrin G and B, αII/βII-spectrin and βIV-spectrin partici-
pate in the transport of ion channels and contribute to the assembling
of axonal proteins at the node of Ranvier (Rosenbluth, 1976; Rasband et
al., 1999; Rios et al., 2003; Devaux et al., 2003, 2004; Chen et al., 2004;
Hartline and Colman, 2007; Duflocq et al., 2008; Susuki et al., 2013;
Battefeld et al., 2014; Arancibia-Carcamo and Attwell, 2014; Barry et
al., 2014). Astrocytes are often located at the vicinity of the nodes of
Ranvier (Hildebrand, 1971a, b), but their role is not known.
Oligodendrocytes can generate between 20 and 60 myelinating
processes with internodal lengths of about 20 μm–200 μm (Hildebrand
et al., 1993). The estimated surface area of one oligodendrocyte, once
the myelin membrane is “unfolded”, is 5–50 × 10⁠3 μm⁠2 (Baron and
Hoekstra, 2010). Therefore, oligodendrocytes are one of the cell types
in the body with the largest surface membrane.
Oligodendrocytes are connected with each other and with astrocytes
through gap junctions thus forming a glial syncytium in the white mat-
ter tracts (Bedner et al., 2012; Nualart-Marti et al., 2013).
Myelin is composed of cholesterol (26%); glycosphingolipids, in par-
ticular galactocerebrosides and sulphatides (31%); plasmalogens (20%);
phospholipids and gangliosides, particularly GM4; and proteins (30%)
(Kursula, 2001, 2008; Chrast et al., 2011; Saher and Stumpf, 2015;
Schmitt et al., 2015). The principal proteins are myelin basic protein
(MBP), proteolipid protein (PLP) and its isoform DM20, 2’,3’-cyclic
nucleotide-3’phosphodiesterase (CNP), myelin-associated glycoprotein
(MAG), myelin oligodendrocyte glycoprotein (MOG), myelin/oligoden-
drocyte specific protein (MOSP), myelin/oligodendrocyte basic protein
(MOBP), oligodendrocyte-myelin glycoprotein (OMgp), transferrin, car-
bonic anhydrase, claudin 11, connexins 32 and 47 (Cs32 and Cx47)
and tetraspan-2, among other minority proteins (Chen et al., 2006; Jahn
et al., 2009; Harauz et al., 2009; Llorens et al., 2011; Raasakka and
Kursula, 2014; McKerracher and Rosen, 2015). MBP and PLP represent
80% of the total myelin protein.
Nodes of Ranvier are enriched in certain myelin- and axon-derived
proteins—netrin, contactin 1 and 2, neurofascin 155, neurofascin 186,
contactin-associated proteins (Caspr 1 and 2)—which interact to bind
the myelin sheath to the axon at the free borders of myelin, together
with extracellular matrix proteins such as brevican, versican and N-CAM
variant (Rasband, 2011; Thaxton et al., 2011; Susuki et al., 2013;
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Because of the large area of oligodendrocytes and cellular processes
including myelin, these cells would be very vulnerable to energy me-
tabolism deficiencies. Oligodendrocytes and myelin in the developing
brain are indeed very vulnerable to hypoxia. However, mature oligoden-
drocytes are equipped with metabolic mechanisms that can cope with
metabolic insults. These include high levels of glutathione which pro-
tects oligodendrocytes from oxidative damage, switching from an oxida-
tive to a glycolytic metabolism; myelin compaction and low turn-over of
myelin proteins; and axon-myelin interactions which are mutually sup-
portive (Back et al., 1998; Brown et al., 2001; Morland et al., 2007;
Funfschilling et al., 2012; Toyama et al., 2013; Hirrlinger and Nave,
2014; Roth and Núñez, 2016).
Oligodendrocytes have an elaborate network of microtubules com-
posed of microtubule-associated proteins MAP2 and tau whose assem-
bly depends on the interaction of several kinases including Fyn kinases
and microtubule-severing proteins such as stathmin (Richter-Landsberg,
2000). Alteration of the cytoskeleton in oligodendroglial cells occurs
in tauopathies in which hyper-phosphorylated tau is accumulated and
disrupts oligodendroglial microtubules (Richter-Landsberg, 2008). Since
the oligodendroglial microtubules participate in the translocation and
sorting of MBP and CNP, their alteration may render myelin vulnerable
(Bauer et al., 2009). Abnormal tau inclusions in glial cells in tauopathies
have functional consequences (Kahlson and Colodner, 2016).
2. Development of oligodendroglia and myelin
Oligodendrocyte precursor cells (OPCs) proliferate in the neuroep-
ithelium of the subventricular zone and migrate to the future white mat-
ter through extending and retracting cell processes until their definitive
placements (Baumann and Pham-Dinh, 2001; Kirby et al., 2006; Miller
and Mi, 2007; Hughes et al., 2013). This process is modulated by self-re-
pulsive movements which allow a certain separation between neighbor-
ing cells (Jarjour et al., 2003; Hughes et al., 2013). Oligodendrocytes
during development are called pre-oligodendrocytes, immature oligo-
dendrocytes, myelinating and mature oligodendrocytes, each one char-
acterized by very specific morphological and biochemical properties.
Differentiation of OPCs to oligodendrocytes depends on the availability
of certain growth and survival factors such as platelet-derived growth
factor A (PDGF)-A, fibroblast growth factor 2 (FGF-2), insulin-like
growth factor 1 (IGF-1), ciliary neurotrophic factor (CNTF) and neu-
rotrophin 3 (NT-3); some cells remain as OPCs whereas redundant cells
are eliminated by apoptosis (Barres et al., 1992; Raff et al., 1993; Barres
and Raff, 1993; Trapp et al., 1997; Miller, 2002).
Although OPCs can differentiate into oligodendrocytes in the ab-
sence of axons (Abney et al., 1981; Raff et al., 1985), axons control
the development of oligodendroglia in vivo (Wender et al., 1980; Privat
et al., 1981; David et al., 1984; Valat et al., 1988; Barres and Raff,
1993, 1999). Moreover, axon signals mediated by certain transcrip-
tion factors and selected microRNAs, histone deacetylases and the
Wnt/-β-catenin pathway modulate myelin gene expression and myelina-
tion (Fancy et al., 2009; Emery, 2010; Piaton et al., 2010; Taveggia et
al., 2010; Budde et al., 2010; Dugas et al., 2010; Zhao et al., 2010; Kim
et al., 2010; Nave, 2010; Twak et al., 2011).
Myelination is also triggered by functional activity of neurons, me-
diated by ATP and adenosine signals which regulate cross-informa-
tion between axons, astrocytes and oligodendrocytes, in parallel with
down-regulation of PSA-NCAM and LINGO-1 (Demerens et al., 1996;
Charles et al., 2000; Mi et al., 2005; Ishibashi et al., 2006; Brinkmann
et al., 2008; Gyllensten and Malmfors, 2009). Synaptic activity con-
tributes to the regulation of myelination (Kukley et al.,
2007; Ziskin et al., 2007; Gibson et al., 2014; Hines et al., 2015; Mensch
et al., 2015; Koudelka et al., 2016).
Myelination is a complex phenomenon which wraps the axon with
concentric bilayers (Pedraza et al., 2001; Ffrench-Constant et al., 2004;
Simons and Trotter, 2007; Bauer et al., 2009). The process of axon
myelination is not uniform but varies along the segment of the involved
axon. MBP is produced in the distal parts of oligodendrocytes closest to
axons and then MBP progresses from the outside to the inside (Ainger
et al., 1993, 1997; Snadeiro et al., 2014). PLP is transported to myelin
by vesicular transport and interacts with MBP in the presence of neu-
ronal signals; interaction between the neuron and MBP is necessary
for myelin protein clustering (Fitzner et al., 2006). Galactocerebroside
(galactosylceramide: GalC) is also incorporated at the same time; thus,
neuron-oligodendroglial interactions are mandatory for proper myelin
biogenesis (Trajkovic et al., 2006; Simons and Trajkovic, 2006).
Myelin compaction is regulated by several factors, among them CNP,
the deficiency of which leads to increased myelin compaction (Snaidero
et al., 2014). Conversely, over-expression of CNP leads to focal areas of
loose myelin compaction (Gravel et al., 1996). MBP then aggregates and
modifies its conformation, resulting in a very stable and resistant pro-
tein which limits the entry of other molecules (Aggarwal et al., 2011a,
b; Aggarwal et al., 2013; Bakhti et al., 2013a, b). Myelin connects at
their edges by tight junctions enriched in claudin-11 (Gow et al., 1999;
Morita et al., 1999).
During myelination, molecular clustering occurs at the nodes of Ran-
vier which involves axonal adhesion molecule neurofascin 186, βIV
spectrin, βII spectrin, ankyrin G, voltage-gated sodium channels, volt-
age-gated potassium channels, TAG-1 and actin, together with glial cell
adhesion molecule neurofascin 155, axonal contactin and Caspr (Pan
and Chan, 2017). Ankyrin deficiency alters the structure of the nodes of
Ranvier and results in axonal degeneration (Saifetiarova et al., 2017).
Caspr deficiency manifests by nodal disruption, disorganization of the
microtubules and axonal swellings (Garcia-Fresco et al., 2006).
In addition to neuron-glia interactions, other extrinsic and intrin-
sic factors modulate OPC differentiation and myelination; these include
hormones acting on specific receptors, cytokines and enzymes, some of
them stimulators and others repressors (McTigue et al., 1998; Noble et
al., 1988; Wang et al., 1998; Stolt et al., 2002; Calza et al., 2002; Valerio
et al., 2002; Klein et al., 2002; Larsen et al., 2006; Kotter et al., 2006;
Fancy et al., 2009; Emery et al., 2009; Meijer et al., 2012; Bankston et
al., 2013).
3. Diversity of OPCs/NG2-glia
OPCs are also called NG2-glia because of their expression of pro-
teoglycan GSPG4 (NG2). These cells are not only found during the de-
velopment of the nervous system; OPCs are present in the adult brain
and show particular features distinct from those seen in embryonic
OPCs (Káradóttir et al., 2008; Tripathi et al., 2011; Clarke et al., 2012;
Vigano et al., 2013; Crawford et al., 2016). OPCs/NG2-glia is consid-
ered the fourth element in the adult central nervous system constitut-
ing about 5–10% of the total cell population (Scolding et al., 1998;
Horner et al., 2000; Dawson et al., 2003; Peters, 2004). Adult OPCs
have the capacity to produce myelinating oligodendrocytes (Tripathi et
al., 2010; Zawadzka et al., 2010), thus contributing to oligodendrocyte
and myelin repair in the adult CNS (Tognatta and Miller, 2016). Indeed,
NG2-glial cells are stem cells as they represent the major proliferative
cell population in the adult CNS and have the capacity to differenti-
ate into different cell types in addition to oligodendrocytes (Psachoulia
et al., 2009; Simon et al., 2011; Dimou and Gotz, 2014; Crawford
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2011; Vigano et al., 2016). For example, a subset of OPCs in the CA1
region of the mouse hippocampus expresses S100β, thus suggesting that
these cells may act as precursors of astrocytes (Moshrefi-Ravasdjani
et al., 2017). Human OPCs are also able to transform into astrocytes
(Windrem et al., 2004; Sim et al., 2006, 2011). In addition, one NG2 can
divide asymmetrically producing an oligodendrocyte and one NG2-glia
(Hill et al., 2014). Whether adult OPCs are able to generate neurons
is a matter of controversy. However, OPCs have been reported to be a
source of pyriform pyramidal neurons in the adult rodent brain (Rivers
et al., 2008; Guo et al., 2010), and adult OPCs removed from brain
can transform into neurons in vitro or when inoculated into developing
brains (Battefeld et al., 2014; Nunes et al., 2003). Furthermore, NG2 im-
munoreactivity is not restricted to a subpopulation of glial cells since
pericytes also express NG2 (Ozerdem et al., 2001).
OPCs in the developing mouse brain arise from three waves and from
different regions; progeny of the second and third waves persists until
adulthood with a certain overlap and reconstructive capacities of the
last generated OPCs (Kessaris et al., 2006; Dimou et al., 2005; Rowitch
and Kriegstein, 2010; Tomassy et al., 2014). Regional heterogeneity of
OPCs implies a different response to particular growth factors and sensi-
tivity to determined signaling pathways even in close areas such as the
ventral and dorsal spinal cord of the mouse (Cai et al., 2005; Fogarty
et al., 2005; Vallstedt and Kullander, 2013). Important differences also
exist between spinal, and cortical and white matter OPCs (Hildebrand
et al., 1993; Chong et al., 2012; Hill et al., 2013; Vigano et al., 2013;
Eugenin-von Bernhardi and Dimou, 2016; Naruse et al., 2017).
The region of origin also determines future functional capacities of
the progeny as responses to demyelination and susceptibility to age-as-
sociated functional decline (Crawford et al., 2016; Ornelas et al., 2016).
OPCs have the capacity to proliferate, migrate and differentiate follow-
ing distinct insults, and they play some role in axon regeneration (Tan
et al., 2005; Hughes et al., 2013). However, OPCs in the white mat-
ter differ from those of the grey matter in many ways including prolif-
eration capacities, response to certain growth factors and plastic prop-
erties among others (Dimou et al., 2008; Kang et al., 2010; Young et
al., 2013; Hill et al., 2013; Vigano et al., 2013; Serwanski et al., 2017;
Hill et al., 2014; Dimou and Gotz, 2014). Certain OPCs express the
G-protein coupled receptor 17 (GPR17) (Chen et al., 2009; Boda et al.,
2011; Fumagalli et al., 2011) which is associated with higher capacity
of differentiation into mature oligodendrocytes following cerebral injury
(Vigano et al., 2016; Bonfanti et al., 2017).
Neurons can establish synaptic-like structures with NG2-glia, at least
in particular regions and species (Bergles et al., 2000; Lin et al., 2005a,
b), whose activation produces bursts of miniature potentials in NG2-glia
mediated by α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
(AMPA) glutamate receptors (Bergles et al., 2000; Ziskin et al., 2007).
In addition to AMPA receptors, NG2-glia expresses N-methyl-D-aspar-
tate (NMDA) receptor, acetylcholine, γ-aminobutyric acid A (GABA⁠A)
and other receptors (Williamson et al., 1998; De Angelis et al., 2012;
Dzamba et al., 2013). NG2-glia also expresses the post-synaptic density
protein 95 (PSD-95) (Sakry et al., 2011). Therefore, neurons can regu-
late proliferation and differentiation of NG2-glia through synaptic sig-
nals (Lin et al., 2005a, b; Kukley et al., 2010; Mangin et al., 2012; Sun
and Dietrich, 2013; Hill et al., 2014; Gibson et al., 2014; Dimou and
Gallo, 2015).
4. Expression of neurotransmitter, hormone receptors and ion
channels in oligodendrocyte lineage
A plethora of neurotransmitter and other receptors are expressed in
OPCs and at different stages of oligodendroglial differentiation and mat-
uration; these modulate, after specific ligand binding, various stages of
oligodendrocyte development (Marinelli et al., 2016). GABA⁠B receptors
are expressed at early stages and their activation induces proliferation
and migration of OPCs (Luyt et al., 2007). NMDA, AMPA and kainate
receptors are expressed in immature and myelinating oligodendrocytes
favoring differentiation and myelination in physiological conditions but
also contributing to oligodendroglial damage in ischemia and excito-
toxic injury (Salter and Fern, 2005; Micu et al., 2006; Káradóttir et al.,
2005).
5-hydroxytryptamine (5-HT) receptor subtypes 1 A and 2 A are ex-
pressed in immature and myelinating oligodendrocytes (Fan et al.,
2015). Its activation after exposure to serotonin interferes with oligo-
dendroglial differentiation and myelinogenesis (Persico et al., 2000; Fan
et al., 2015). Curiously, depression is accompanied by reduced oligo-
dendroglia, expression of myelin-related genes and decreased MBP lev-
els in various brain regions (Aston et al., 2005; Yamazaki et al., 2007;
Regenold et al., 2007). Dopamine receptors D2 and D3 are expressed
in oligodendrocyte precursors where they are probably involved in the
regulation of differentiation and myelin formation (Bongarzone et al.,
1998). Adult oligodendrocytres in rats also express D2 and D3 receptors
but their function is not known (Rosin et al., 2005). Pre-oligodendro-
cytes express α- and β-adrenoreceptors whose activation inhibits their
proliferation (Ghiani et al., 1999). Cholinergic receptors are present in
OPCs and oligodendrocytes at different phases; acetylcholine via mus-
carinic receptors potentiates proliferation (De Angelis et al., 2012).
OPCs exhibit opioid receptors (Knapp et al., 1998). Dinorphin and
pro-encephalin-derived peptides are produced at different stages of
oligodendrocyte maturation, thus suggesting an autocrine/paracrine ef-
fect on cell survival and development (Knapp et al., 2011). However,
perinatal exposure to methadone and bupremorphine alter myelination
in the developing rat brain (Eschenroeder et al., 2012; Vestal-Laborde et
al., 2014).
ADP and ATP stimulate OPC migration through specific receptors
(Agresti et al., 2005) but ATP may also facilitate calcium-mediated ex-
citoxicity and oligodendrocyte damage (Butt, 2006).
Prolactin activates proliferation, maturation and myelination of
oligodendrocytes (Gregg et al., 2007). Dexametasone enhances myeli-
nation at early stages but reduces myelin formation at advanced stages
of development (Almazan et al., 1996). Increased proliferation and
oligodendroglial death, suggesting decreased lifespan, and increased
oligodendroglial turnover are found in female and castrated male rats
(Cerghet et al., 2009). Thyroid hormones activate the expression of
myelin-related genes (Farsetti et al., 1991; Tosic et al., 1992;
Rodriguez-Peña et al., 1993). Other factors influencing oligodendro-
cyte development are cannabinoids, liver X receptor, retinoic acid,
prostaglandins and peroxisome proliferator activated receptor γ
(Marinelli et al., 2016).
Finally, different ion channels are expressed in OPCs and oligoden-
drocytes including voltage-gated sodium channels (Tong et al., 2009),
voltate-gated calcium channels (Verkhratsky et al., 1990) and diverse
potassium channels (Buttigieg et al., 2011; Wang et al., 2011; Hawkins
and Butt, 2013; Moroni et al., 2015; Battefeld et al., 2016; Livesey
et al., 2016; Fang et al., 2017; Brasko et al., 2017; Larson et al.,
2018) which participate in glial cell proliferation, regeneration, oligo-
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which modulate oligodendroglial responses to ischemia, excitotoxicity
and seizures, among other pathological settings.
5. Diversity of oligodendrocytes
Transcriptomic profiles of neurons, astrocytes and oligodendroglia
have been identified using high-throughput methods (Cahoy et al.,
2008; Zhang et al., 2014; Moyon et al., 2015; van Bruggen et al., 2017).
Single-cell RNA sequencing revealed different subpopulations of oligo-
dendrocytes from several brain regions of juvenile and adult mouse
brain (Zeisel et al., 2015; Marques et al., 2016). A single cluster of OPCs
was found in the first studies (Marques et al., 2016; Hochgerner et al.,
2017). However, several OPC clusters were recognized thereafter in the
adult murine spinal cord (Habib et al., 2016). Likewise, several clusters
of oligodendrocytes have been described in the mouse CNS (Tasic et al.,
2016; Habib et al., 2017; Hochgerner et al., 2017).
Gene expression studies have also identified subpopulations of OPCs
in human adult white matter and fetal forebrain (Sim et al., 2006,
2011), and in human (and murine) ventral midbrain during develop-
ment (La Manno et al., 2016). Similar analysis has been extended to
human oligodendrocytes, further confirming different clusters of oligo-
dendrocytes and precursors in human brain (Darmanis et al., 2015;
Spaethling et al., 2017; Habib et al., 2017; Lake et al., 2017).
All this information supports pioneering observations by Pio del
Rio-Hortega describing different types of oligodendroglial cells. How-
ever, available information is not uniform and it is difficult, at present,
to consolidate clear-cut profiles for different clusters/types of oligoden-
drocytes. There is probably a more complex scenario because transcrip-
tion is modifiable depending on the function and physiological state of
the cells.
6. Signals involved in OPC generation, oligodendroglia
differentiation and myelination
Major knowledge of OPC generation comes from the study of the
mouse spinal cord and forebrain. In the spinal cord, the first wave
of generation occurs at embryonic day 12, originates from the ven-
tral neural tube and depends upon sonic hedgehog (SHH) and Nkx6.1
and Nkx6.2 regulation of Olig 1 and Olig2 transcription (Orentas et al.,
1999; Lu et al., 2000; Vallstedt et al., 2005). A second wave originates
at embryonic day 15 from the dorsal spinal cord; it is not dependent on
SHH but it is regulated by Dbx1 and As11 and requires fibroblast growth
factor enhancement and decreased bone morphogenic protein signaling
(Vallstedt et al., 2005; Cai et al., 2005; Fogarty et al., 2005; Sugimori et
al., 2008). A third wave occurs at birth (Rowitch and Kriegstein, 2010).
In the forebrain, the first wave comes from the medial ganglionic
eminence upon SHH and Nkx.2 mediation (Nery et al., 2001;
Tekki-Kessaris et al., 2001; Kessaris et al., 2006), and it spreads to the
entire forebrain (Kessaris et al., 2006; Klambt, 2009). The second wave
comes from the lateral ganglionic eminence under the control of Gsx2
(Chapman et al., 2013) and it populates all the forebrain (Kessaris et al.,
2006; Klambt, 2009). The third wave occurs at birth, and derives from
dorsal and outer subventricular zones through Emx1 extending to the
corpus callosum and capsular white matter (Kessaris et al., 2006).
Such detail in human brain is not available although OPCs first
appear approximately at nine weeks of gestation and proliferate until
about 18 weeks of gestation; oligodendroglia start to differentiate until
about 27 weeks of gestation (Back et al., 2001; Jakovcevski et al., 2009;
Sim et al., 2011)
Early oligodendroglial differentiation, at least in the murine brain,
is mediated by activation of transcription factors Znf488 and Znf536,
down-regulation of Sox2, up-regulation of Sox8, Sox9, Sox 10, Olig1 and
Olig 2 (Kuhlbrodt et al., 1988; Wegner and Stolt, 2005; Yang et al., 2013;
Wang et al., 2014). At early stages, human and murine cells also ex-
press platelet derived growth factor receptor α (PDGFα), gangliosides
(as revealed by the antibody A2B5) and NG2 (Hart et al., 1989; Noble
et al., 1988; Wolswijk and Noble, 1989; Richardson et al., 1988; Roy et
al., 1999; Chang et al., 2000; Dawson et al., 2000; Levine et al., 2001;
Sim et al., 2006, 2011; Wang et al., 2014). The transition of OPCs to
post-mitotic oligodendrocytes is characterized by chromatin condensa-
tion with heterochromatin formation (Huang et al, 2015), up-regulation
of selected microRNAs and silencing of genes involved in cell prolifera-
tion including PDGF, FGF and Wnt, among other factors (Yu et al., 2010,
2013; Zhao et al., 2010; Dugas et al., 2010; Ackerman et al., 2015; Giera
et al., 2015; Barca-Mayo and Lu, 2012; Magri et al., 2014; Mitew et al.,
2014; Fitzpatrick et al., 2015). Wnt/β-catenin pathways play different
roles in oligodendrocyte development and myelination in different brain
regions and at different stages (Guo et al., 2015). These transcription
factors are controlled by epigenetic remodeling of the chromatin by hi-
stone acetylation and methylation. Histone deacetylases 1 and 2 (HDAC
1 and 2) actively participate in this process (Marin-Husstege et al., 2002;
Shen et al., 2005; Liu et al., 2007a, 2015).
Early stages of oligodendrocyte lineage are identified by the expres-
sion of Olig1, Olig2 and Nkx2.2 (Liu et al., 2007b). PDGF-Rα, NG2,
Olig1, Olig 2, Sox 10 and A2B5 are OPC differentiation and pre-oligo-
dendrocyte markers. Loss of PDGF-Rα and NG2, and increased expres-
sion of surface lipid sulfatide, galactocerebroside and CNP, together
with Olig 1 and Olig 2, are characteristic of immature oligodendrocytes
(Marinelli et al., 2016).
After oligodendrocyte differentiation, myelination is triggered by
myelin regulatory factor (MYRF) which is expressed in post-mitotic
oligodendrocytes (Cahoy et al., 2008). This is accompanied by increased
expression of MBP, MAG, PLP1, MOG and CNP which have MYRF bind-
ing motivs in their promoters (Emery et al., 2009; Koenning et al., 2012;
Bujalka et al., 2013; McKenzie et al., 2014; Emery and Lu, 2015). At
this time, oligodendrocytes also produce sulfatides and galactocerebro-
sides as main lipid components of myelin. MBP, MAG, MOG and PLP are
mainly found in myelin under physiological conditions in the mature
brain; carbonic anhydrase II, CNP and galactocerebroside can be identi-
fied in oligodendrocytes in brain tissue sections; surface lipid sulfatide,
Olig1, Olig2 and Sox 10 are additional markers expressed in myelinating
oligodendrocytes (Bradl and Lassmann, 2010; Marinelli et al., 2016).
The role played by neurons and axons during myelinogenesis has
been detailed before. Whether oligodendroglial subtypes depend on the
type of axons and the type of neurons is a matter for study (Ludwin,
1979; Tauber et al., 1980; Tomassy et al., 2014; Battefeld et al., 2016;
Micheva et al., 2016).
7. Oligodendroglia and axon integrity
In addition to studies showing the role of axons in the development
of oligodendroglia, several in vitro and in vivo experimental models have
demonstrated that oligodendroglia are involved in support of axonal
transport and axon integrity (Nave and Trapp, 2008; Lee et al., 2012;
Saab et al., 2013; Beirowski, 2013; Morrison et al., 2013; White and
Krämer-Albers, 2014; Simons et al., 2016). Axon outgrowth is also sus-
tained in part by growth factors such as GDNF and BDNF produced by
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Oligodendrocyte cell death is produced by diphtheria toxin in mice
selectively expressing diphtheria toxin receptor in oligodendoglia or by
conditionally targeting diphtheria toxin to PLP-CrER mice (Ghosh et al.,
2011; Oluich et al., 2012). In all these settings, oligodendroglial cell
death is accompanied by axonal damage with little if any myelin de-
struction and with the absence of secondary immune reaction (Pohl et
al., 2011; Oluich et al., 2012).
Mice with altered expression of PLP, a protein primarily affected
in certain forms of Pelizaeus-Merzbacher disease, is manifested by de-
myelination and axonal damage (Sidman et al., 1964; Griffiths et al.,
1981; Schneider et al., 1992; Gotow et al., 1999; Al-Saktawi et al.,
2003; Karim et al., 2007; Mayer et al., 2011). However, axonal damage,
mainly or exclusively, is found in PLP1 null mice (Griffiths et al., 1998;
Edgar et al., 2004), presumably due to altered axonal transport (Edgar
et al., 2004, 2010). Axonal mitochondrial dysfunction via altered meta-
bolic coupling occurs in PLP-deficient mice (Yin et al., 2016).
Mice lacking CNP show early axonal damage and disruption of the
paranodal architecture, followed by axonal degeneration and myelin
damage (Lappe-Siefke et al., 2003; Rasband et al., 2005; Edgar et al.,
2009). This may be due to increased myelin compaction interfering with
oligodendrocyte metabolic effects on axons (Edgar and Nave, 2009).
Finally, transgenic mice lacking MAG have subtle changes in myelin
structure accompanied by reduced axon caliber, reduced neurofilament
phosphorylation and progressive axon loss (Fruttiger et al., 1995; Yin et
al., 1998; Pan et al., 2005).
In addition to the involvement of particular myelin proteins in the
maintenance of axon stability, other data provide strong support for
the notion of metabolic interaction between oligodendrocytes and ax-
ons. During development, oligodendrocytes import glucose and lactate
(Rinholm et al., 2011). However, mature oligodendrocytes can survive
only with glycolysis. Conditional Cox10 mutant mice in which oligoden-
droglia (and Schwann cells) fail to assemble mitochondrial complex IV
(cytochrome c oxidase: COX) show peripheral but not central myelin ab-
normalities. These alterations are accompanied by increased brain lac-
tate concentrations, thus suggesting that enhanced glycolysis in oligo-
dendroglia, aimed at preserving energy supply, may maintain axon in-
tegrity in spite of altered mitochondrial metabolism in oligodendrocytes
(Funfschilling et al., 2012).
Blood-derived glucose taken up by oligodendrocytes through glial
glucose transporter 1 (GLUT1) is metabolized via glycolysis to produce
piruvate and lactate which are delivered to the axons through specific
solute carriers, the monocarboxylase transporters (Saab et al., 2013).
Solute carrier (SLC) protein family 16 includes monocarboxylate trans-
porters (MCT) located in cell membranes (Pierre and Pellerin, 2005).
MCT1 is mainly expressed in oligodendrocytes (Rinholm et al., 2011;
Lee et al., 2012). Inhibition of MCT1 in organotypic cultures of the
spinal cord in glucose-deprived media is toxic to neurons but not to
oligodendroglial cells; the effects on neurons are reversed with the ad-
dition of lactate into the medium (Lee et al., 2012). in vivo experiments
geared at inducing reduction of MCT1 activity result in axonal dam-
age (Lee et al., 2012). Together, these observations suggest that MCT1
serves as intermediate transporter of metabolites necessary to energy
metabolism in neurons.
Oligodendrocyte and axon interactions are not only bi-directional;
astrocytes also participate as crucial players. Oligodendrocytes are con-
nected with astrocytes through gap junctions composed of connex-
ins (Cx); Cx32 and Cx47 are synthesized by oligodendrocytes, and
Cx30 and Cx43 by astrocytes (Orthmann-Murphy et al., 2007). Mice
lacking either Cx47 or Cx32 are viable but transgenic mice lacking
both Cx32 and Cx47 show thin or ab
sent myelin sheaths, vacuolation, enlarged periaxonal collars, oligoden-
drocyte cell death, and axonal loss (Menichella et al., 2003). Double mu-
tations of Cx30 and Cx47, affecting oligodendroglial and astrocytic com-
ponents of gap junctions, show severe vacuolization and myelination de-
fects in all white matter tracts of the CNS, accompanied by decreased
numbers of oligodendrocytes, severe astrogliosis and microglial activa-
tion in white matter tracts (Tress et al., 2012). Cx47 is also expressed in
OPCs and its expression increases in co-cultures with astrocytes which
induce proliferation of oligodendrocytes via Cx47-mediated activation
of the ERK/Id4 pathway and sphingosine-1-phosphate receptors 3 (Liu
et al., 2017a, b; Xu et al., 2017). Cx26 is localized in individual gap
junctions between astrocytes and in heterotypic gap junctions between
astrocytes and oligodendrocytes (Nagy et al., 2011).
8. Oligodendrocytes in brain aging
Human myelination is uniquely expanded and vulnerable to aging
(Tse and Herrup, 2017). White matter lucencies with age were dis-
covered by neuroimaging studies (Hachinski et al., 1987; Meyer et al.,
1992). Progressive white matter decline in human brain, as revealed
by magnetic resonance imaging (MRI), starts at about 45 years of age
(Bartzokis et al., 2001, 2003; Sperling et al., 2014) and it is enhanced
in Alzheimer’s disease (Bartzokis et al., 2003). This is accompanied by
white matter hyperlucencies which correspond either to areas of poor
perfusion, areas of myelin pallor, or periventricular edema (Barber et
al., 1999; Young et al., 2008; Black et al., 2009; Holland et al., 2008;
Erten-Lyons et al., 2013; Liu et al., 2017a, b), thus indicating that
age-related white matter alterations are multifactorial.
Small blood vessel disease is not uncommon from middle-age on-
wards and it is likely causative of variegated lesions in the white matter
including hypoperfusion, status cribosus, small infarcts or lacunes, and
diffuse white matter demyelination (so called Binswanger encephalopa-
thy when clinically manifestesd as cognitive impairment) (Kalaria et al.,
2015).
All these changes may be silent depending on the degree and local-
tion of lesions but they are also causative of cognitive impairment once
certain thresholds are reached (Ferrer, 2010)
The time of OPC division is increased in old age and therefore oligo-
dendrocyte repair is delayed (Lasiene et al., 2009; Psachuolia et al.,
2009; Zhu et al., 2011). Moreover late oligodendrocyte progenitors are
particularly vulnerable to hypoxia (Back et al., 2002). HDCA1 and Olig2
are downregulated in the aging brain (Shen et al., 2008a, b) thus limit-
ing rates of remyelination.
Oligodendroglial nuclei in the aging white matter show signatures
of oxidative DNA damage which increase in Alzheimer’s disease
(Al-Mashhadi et al., 2015). Oxidative damage likely involves RNA, pro-
teins and lipids, as in other cells and regions. Whether specific oligo-
dendroglial proteins are oxidatively damaged in old age deserves study.
Likewise, further information is needed to learn about the functional in-
tegrity of oligodendrocyte glucose and monocarboxylate transporters in
old age.
9. Oligodendrogliopathy
The term astrogliopathy refers to alterations of astrocytes occur-
ring in diseases of the nervous system, includes reactive astroglio-
sis (mainly manifested as an increase in the amount of GFAP and
in the number of astrocytes containing GFAP), and stresses the car-
dinal role of astrocytic dysfunction in the pathogenesis of neurolog-
ical diseases (Seifert et al., 2006; Pekny and Pekna, 2014; Pekny et
al., 2016; Osborn et al., 2016; Verkhratsky et al., 2017a, b). Astro-
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atrophy/degeneration and loss of function occurring as a primary cause
of a disease or as a factor contributing to the development and progres-
sion of a particular disease (Pekny et al., 2016; Ferrer, 2017).
The term oligodendrogliopathy has developed more recently
(Wenning et al., 2008; Bleasel et al., 2016) to stress the prominent role
of altered oligodendrocytes in the pathogenesis of certain neurological
diseases (Fellner and Stefanova, 2013; Tognata and Miller, 2016; Ettle et
al., 2016a, b). Oligodendrogliopathy is crucial in demyelinating diseases
and most leukodystrophies. Indeed, the term oligodendrogliopathy was
initially coined by Lassman et al. in the context of myein-associated gly-
coprotein deficiency (Lassmann et al., 1997), and astro- and oligoden-
drogliopathy are early events in CNS demyelination (Zhang et al., 2013;
Rone et al., 2016). Yet disturbances of oligodendrocyte function have
also emerged as determining factors in apparently distant diseases such
as psychiatric disorders including schizophrenia and major depression
(Miyata et al., 2015; Birey et al., 2017).
Here, we review oligodendrogliopathy in relevant neurodegenera-
tive diseases with abnormal protein aggregates.
9.1. Multiple system atrophy
Multiple system atrophy (MSA) is a sporadic adult-onset degener-
ative disease manifested clinically by parkinsonism, cerebellar symp-
toms and autonomic dysfunction, and neuropathologically by
degeneration of the olivopontocerebellar system, substantia nigra and
autonomous nervous system, together with the presence of oligoden-
droglial and neuronal inclusions containing abnormal α-synuclein
(Holton et al., 2011). MSA is a prototypic oligodendroglioneural synu-
cleinopathy (Jellinger, 2018) (Fig. 1).
Four stages or grades of neuropathology have been proposed in MSA.
However, differences in the main forms of clinical presentation—ni-
gro-striatal degeneration and olivopontocerebellar atrophy, as well as
individual variations—make practical use of the proposed classification
at advanced stages of the disease difficult (Jellinger et al., 2005; Ozawa
et al., 2004).
Reduced white matter and myelin staining, together with altered
lipid levels, is found in the striatum, cerebellar white matter, fascicles
of the pons and medulla oblongata, and, often, white matter of the cere-
bral hemispheres and internal capsule (Matsuo et al., 1998; Schocke et
al., 2002; Shiga et al., 2005; Blain et al., 2006; Paviour et al., 2007;
Brooks and Seppi, 2009; Prodoehl et al., 2013; Don et al., 2014). These
lesions are accompanied by characteristic oligodendroglial inclusions
called Papp-Lantos inclusions which are the hallmark of the disease
(Papp et al., 1989).
Early studies showed the presence of ubiquitin and tau in these in-
clusions (Abe et al., 1992; Murayama et al., 1992; Papp and Lantos,
1994; Papp et al., 1989; Takeda et al., 1997). Subsequent inquiries
revealed α-synuclein as the main component of oligodendroglial in-
clusions in MSA (Spillantini et al., 1998; Tu et al., 1998;
Fig. 1. α-synuclein-immunoreactive (red) oligodendroglial inclusions in the cerebellar white matter (A, B) and pons (C, D) in multiple system atrophy (MSA). Paraffin sections, nuclei
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Wakabayashi et al., 1998; Gai et al., 2003; Jellinger and Lantos, 2010).
The distribution of α-synuclein deposits correlates with the main
pathological lesions, and the number of inclusions increases with dis-
ease progresion (Papp and Lantos, 1994; Inoue et al., 1997; Halliday
et al., 2011). Abnormal α-synuclein deposits are also found less numer-
ously in the cytoplasm and nuclei of neurons (Papp and Lantos, 1992;
Wenning and Jellinger, 2005).
The source of α-synuclein in MSA oligodendrocytes is controversial.
From very little to nearly no α-synuclein mRNA is expressed in adult
control and MSA oligodendrocytes (Solano et al., 2000; Ozawa et al.,
2001; Miller et al., 2005). However, one study reported mRNA α-synu-
clein expression in oligodendrocytes, although it is not clear whether
the expression is increased in α-synuclein-containing oligodendroglial
inclusions in MSA (Asi et al., 2014). Other surveys showed the presence
of α-synuclein protein in cultured oligodendrocytes (Richter-Landsberg
et al., 2000). Moreover, α-synuclein has been demonstrated in oligo-
dendroglial cell lineage derived from induced pluripotent stem cells (iP-
SCs) from human healthy cases and patients with Parkinson’s disease
and MSA with decreased α-synuclein expression during oligodendrocyte
maturation; transcripts are also detected in human and rodent oligoden-
drocytes isolated by fluorescence-activated cell sorting (FACS) (Djelloul
et al., 2015).
As an alternate proposal, α-synuclein in oligodendrocytes may orig-
inate in neurons and then become trapped by oligodendrocytes.
Monomeric, oligomeric and fibrillar forms of α-synuclein uptake oc-
cur in oligodendrocytes in vitro and in vivo; α-synuclein can transfer
to grafted oligodendroglial cells from host rat brain neurons overex-
pressing human α-synuclein (Reyes et al., 2014). Neuronal to oligoden-
droglia α-synuclein transfer is further supported in transgenic mice ex-
pressing A53 T human α-synuclein enhanced by docosahexaenoic acid
(Kisos et al., 2012). α-synuclein uptake in both neurons and oligoden-
droglia seems to be mediated by endocytosis as dynamin GTPase sup-
pression decreases α-synuclein uptake in neurons and oligodendrocytes
(Konno et al., 2012). Finally, slow degradation of α-synuclein in oligo-
dendroglial cells has been suggested as an accompanying factor in the
generation of Papp-Lantos inclusions (Fellner et al., 2011).
α-synuclein in MSA is abnormally nitrated, phosphorylated and oxi-
dized, and has anomalous solubility (Dickson et al., 1999; Giasson et al.,
2000; Duda et al., 2000; Campbell et al., 2001; Fujiwara et al., 2002;
Hasegawa et al., 2002; Pountney et al., 2004; Tong et al., 2010; Ubhi et
al., 2011).
In addition to abnormal α-synuclein, MSA inclusions contain sev-
eral proteins including synphilin-1, SUMO-1, ubiquitin, FBXO7, dorfin,
PACRG, NUB-1, HtrA2/OMI, XIAP, αB-crystallin, proteasome subunits,
HSP70, HSP90, PDI, p62, NBR1, LRRK2, clusterin, methallothionein-III,
cyclin-dependent kinase 5, mitogen-activated protein kinase, P39, Elk1,
tubulin polymerization-promoting protein p25α (TPPP/p25α), tau,
γ-tubulin, MAP5, histone deacetylase 6, DARPP32, midkine, Rab5,
rabaptin-5, 14-3-3 and AMBRA-1, among others (Abe et al., 1992;
Murayama et al., 1992; Takeda et al., 1997; Spillantini et al., 1998; Gai
et al., 1999; Nakamura et al., 1998, 2000; Piao et al., 2001; Honjyo
et al., 2001; Iwata et al., 2001; Kato et al., 2000; Sasaki et al., 2002;
Wakabayashi et al., 2002; Kawamoto et al., 2002; Hishikawa et al.,
2003; Kovács et al., 2004; Pountney et al., 2005a, b; Tanji et al., 2007;
Song et al., 2007; Taylor et al., 2007; Kovács et al., 2007; Wenning et
al., 2008; Kawamoto et al., 2008; Honjo et al., 2008, 2011; Pountney
et al., 2011; Chiba et al., 2012; Odagiri et al., 2012; Zhao et al.,
2013; Wong et al., 2013; Kawamoto et al., 2014; Miki et al., 2018).
Impaired protesome function and autophagy play key roles in the
pathogenesis of protein aggregates in oligodendrocytes in MSA
(Schwarz et al., 2012).
The meaning of the great number of proteins trapped in oligoden-
droglial inclusions is not known, but some of these proteins are impli-
cated in particular functions. p25α is re-localized in oligodendrocytes in
MSA before the appearance of oligodendroglial inclusions, and the in-
teraction of p25α with MBP is altered (Song et al., 2007). Moreover,
p25α induces α-synuclein aggregation (Lindersson et al., 2005; Kragh et
al., 2009). Therefore, p25α seems to have a double effect, enhancing
α-synuclein aggregation and impairing myelination.
Oligodendroglia inclusions also contain tubulin β-III which co-local-
izes with α-synuclein in abnormal inclusions in certain MSA transgenic
mice (Nakayama et al., 2009). Interactions of tubulin β-III and other cy-
toskeletal proteins, such as tau, with abnormal α-synuclein have dele-
terious effects on the microtubules (Nakayama et al., 2012; Ota et al.,
2014).
Immunoprecipitation studies have also shown abnormal α-synuclein
interactions with Rab3a in the cerebellum and pons in MSA, thus sug-
gesting alterations in membrane and synaptic vesicle trafficking in MSA
(Dalfó and Ferrer, 2005).
The expression of several proteins is increased in the white matter of
affected regions in MSA. For example, ABCA8, an ATP-binding cassette
lipid transporter, which promotes sphingomyelin production in oligo-
dendrocytes, is increased in white matter in MSA (Bleasel et al., 2013).
Transfected human oligodendrocytes with ABCA8 produce an increase
in α-synuclein and p25α (Bleasel et al., 2013), thus suggesting that AB-
CA8 is involved in MSA pathogenesis although not necessarily present
in oligodendroglial inclusions. In the same line, the endoplasmic retic-
ulum stress response is activated at early stages of the disease in areas
with oligodendroglial inclusions (Makioka et al., 2010).
It has been reported that the volume of the nuclei of oligodendro-
cytes is reduced in MSA in regions devoid of inclusions (Uyama et al.,
2009). Yet it is not clear whether the same applies to the nuclei of
oligodendroglia bearing inclusions. Moreover, the number of oligoden-
drocytes seems to be preserved in the white matter in MSA (Ettle et
al., 2016a, b; Nykjaer et al., 2017). On the other hand, the number of
OPCs is increased in MSA, and some OPCs contain α-synuclein inclu-
sions (Ahmed et al., 2013a; May et al., 2014).
Several animal and cell models have been developed to gain un-
derstanding about MSA. Expression of oligodendroglial α-synuclein has
been generated following intrastriatal injection of chimeric viral vectors
expressing α-synuclein under the control of MBP; interestingly, phos-
phorylated and proteinase-resistant α-synuclein is detected in the stria-
tum and substantia nigra, indicating, in addition, the capacity for seed-
ing (Bassil et al., 2017). Other viral vector models are currently assessed
in rodent and nonhuman primates (Mandel et al., 2017).
Transgenic models reproduce α-synuclein overxpression and phos-
phorylation in oligodendroglia under the control of myelin gene pro-
moters, either MBP, PLP or CNP (Kahle et al., 2002; Yazawa et al.,
2005; Shults et al., 2005; Tank et al., 2014; Fernagut et al., 2014;
Fellner et al., 2015; Bleasel et al., 2016; Overk et al., 2018). All of them
show, albeit with particularities, clinical phenotype and neuropathol-
ogy reminiscent of MSA (Kuzdas et al., 2013; Boudes et al., 2013;
Flabeau et al., 2014). Myelin loss occurs in every model, and reduced
numbers of oligodendroglia are reported in some of them (Yazawa et
al., 2005; Stemberger et al., 2010; Stefanova et al., 2012). The num-
ber of OPCs is increased in transgenic mice generated with MBP pro-
moter (May et al, 2014). Additional evidence shows that α-synuclein
overexpression impairs the maturation of OPCs and reduces the pro-
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sion in oligodendrocytes in primary and stem cell-derived oligodendro-
cytes impairs myelin formation (Ettle et al., 2016a, b).
Other factors condition α-synuclein alterations and oligodendrocyte
deterioration in MSA. α-synuclein pathology and myelin damage are
enhanced following mitochondrial inhibition and oxidative stress in
transgenic mice (Stefanova et al., 2005; Ubhi et al., 2009). This is
reproduced in vitro when oxidative stress induces α-synuclein aggre-
gation in cultured oligodendroglia (Riedel et al., 2011; Pukaβ and
Richter-Landsberg, 2014; Pukaß et al., 2015). α-synuclein accumula-
tion is also attained following proteasomal inhibition (Stefanova et al.,
2012). This is further supported by studies in vitro demonstratring al-
tered autophagy and proteasomal activity in oligodendrocytes following
α-synuclein expression (Schwarz et al., 2012). The effects of α-synuclein
uptake and mitochondrial damage have been sustained in astrocytes af-
ter uptake of α-synuclein monomers (Lindström et al., 2017); no similar
studies are available regarding oligodendrocytes. Interestingly, oxida-
tive and proteolytic stress also induces the recruitment of tau in oligo-
dendrocytes overexpressing α-synuclein (Riedel et al., 2009).
Finally, transgenic mice expressing oligodendroglial α-synuclein un-
der the MBP promoter show reduced GDNF protein expression and pre-
served GDNF mRNA, suggesting that abnormal α-synuclein brings about
post-translational effects on GDNF expression. Normalization of GDNF
levels ameliorates behavior and neuropathological deficits in these mice
(Ubhi et al., 2010, 2012).
Mechanisms of disease progression are not known but in vitro α-synu-
clein uptake studies, α-synuclein accumulation in oligodendrocytes in
certain murine paradigms, and more importantly, transmission studies
of MSA to transgenic mice are in line with the concept of cell-to-cell
transmission of abnormal MSA α-synuclein. in vitro studies demonstrate
α-synuclein uptake by oligodendrocytes and formation of intracellular
aggregates reminiscent of oligodendroglial inclusions in MSA (Kisos et
al., 2012; Konno et al., 2012). α-synuclein transmission to oligodendro-
cytes and precursors, in addition to neurons, occurs in embryonic rat
brain tissue grafted to mice producing human α-synuclein under a viral
vector (Reyes et al., 2014). Redistribution of α-synuclein from neurons
to oligodendrocytes is observed in double-transgenic mice (Rockenstein
et al., 2012). Most clear evidence of α-synuclein transmission comes
from the observation that MSA homogenates inoculated into the brain
of mice produce a neurodegenerative disease characterized by the accu-
mulation of abnormal α-synuclein in neurons and oligodendroglia sim-
ilar to that seen in human MSA (Watts et al., 2013). The same results
are obtained after inoculation of homogenates obtained from other se-
ries of MSA cases thus replicating first studies; importantly, no similar
oligodendroglial inclusions are found after inoculation of homogenates
from cases with Lewy body disease, thus suggesting the existence of spe-
cific MSA strains (Prusiner et al., 2015). These findings together with
propagation of MSA-derived α-synuclein in cultured cells (Woerman et
al., 2015) suggest that MSA has the properties of a prion-like disease
with the capacity to propagate to oligodendroglail cells (Woerman et al.,
2017).
Interestingly, α-synuclein induces fibrillization of tau, and co-incu-
bation promotes fibrillization of both proteins (Giasson et al., 2003).
Double-transgenic mice expressing both α-synuclein and tau show syn-
ergistic fibrillization of these two proteins (Fillon and Kahle, 2005).
Concurrence of α-synuclein and tau in abnormal neurites and less com-
monly in neurons in the Contursi kindred of familial PD rarely co-lo-
calizes with almost complete spatial disparity (Duda et al., 2002). Rare
tau granular deposits are seen in oligodendrocytes in MSA which do
not co-localize with α-synuclein deposits thus suggesting that tau ag-
gregation might be another pathway of oligodendroglial degeneration
in this disease (Nigashi et al., 2011; Jellinger, 2012). Oxidatively mod-
ified α-synuclein is de
graded by the proteasome and it plays a pro-aggregative role for tau in
oligodendroglial cells exposed to particular settings (Riedel et al., 2009).
9.2. Lewy body diseases
Lewy body diseases (LBD) include Parkinson’s disease (PD) and De-
mentia with Lewy bodies (DLB). Both are characterized by distinct pre-
motor symptoms followed by parkinsonism due to the involvement of
the autonomic nervous system, selected nuclei of the medulla oblongata
and pons, and eventually the substantia nigra pars compacta, respec-
tively. Cognitive deficits may appear with disease progression in PD,
whereas dementia is an early symptom in DLB. Involvement of the cere-
bral cortex, although with differences in PD and DLB, is causative of
cognitive impairment and dementia. The term LBD comes from the pres-
ence of intraneuronal inclusions named Lewy bodies composed of ab-
normal α-synuclein which is nitrated, phosphorylated, abnormally con-
formed and aggregated, and with altered solubility; abnormal α-synu-
clein is also accumulated in aberrant neurites (Jellinger, 2011; Ince,
2011; Revesz et al., 2015).
The putative progression of PD has been classified into six stages
from the medulla oblongata (and olfactory bulb) to the pons, mid-
brain, limbic system, diencephalic nuclei and neocortex (Braak et al.,
2003, 2004). Involvement of the autonomic nervous system is also con-
sidered an early stage of PD pathology. Cases without clinical symptoms
or with pre-motor symptoms (without parkinsonism) and with Lewy
bodies and neurites in the lower parts of the brain stem are catego-
rized as pre-motor or incidental PD (Dickson et al., 2008; Ferrer et al.,
2012). Yet some incidental LBD cases have LBs in the cerebral cortex
and these cases have been categorized as putative preclinical stages of
DLB (Frigerio et al., 2011).
White matter involvement in PD is limited, whereas white matter
involvement in DLB is variable, mainly affecting the posterior lobes,
and often linked with associated Alzheimer’s disease (AD) pathology
(Bohnen and Albin, 2011; Nedelska et al., 2015; Firbank et al., 2016;
Joki et al., 2018). Decreased size of oligodendroglial nuclei has been de-
scribed in LBD independently of the concomitant AD pathology (Gagyi
et al., 2012). The reasons and functional consequences are not known.
α-synuclein-positive inclusions in astrocytes and oligodendroglia are
found in the midbrain in PD; they are composed of filamentous struc-
tures about 25–40 nm in diameter, and their presence correlates with
neuronal loss, at least in the substantia nigra (Wakabayashi et al., 2000).
Oligodendroglial inclusions containing abnormal α-synuclein have also
been reported in many nuclei and fiber tracts of the brain stem contain-
ing Lewy bodies or Lewy neurites (Seidel et al., 2015).
Oligodendrocytosis occurs in the substantia nigra and striatum fol-
lowing acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) treatment in mice and macaques, respectively, used as models
of PD (Annese et al., 2013). This suggests that oligodendrocytes are vul-
nerable to this treatment although its implication in LBDs is not known.
The meaning of reported auto-antibodies against MAG in parkinsonian
patients without correlation with disease severity (Papuć et al., 2016)
deserves further study.
There is a bulk of information regarding prion-like propagation of
neuronal α-synuclein in several in vivo and vitro paradigms of LBDs
(Ulusoy et al., 2015; Rey et al., 2016; Shimozawa et al., 2017; Choi et
al., 2018; just to include additional references to those signaled in pre-
vious paragraphs).
As already mentioned in MSA, oligodendrocytes can take up re-
combinant α-synuclein monomers, oligomers and, to a lesser extent,
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droglial cells from host rat brain neurons overexpresing α-synuclein
(Reyes et al., 2014). Curiuosly, no oligodendroglial α-synuclein-im-
munoreactive inclusions are produced after inoculation of brain ho-
mogenates from cases with LBD in striking contrast with the inocula-
tion of MSA homogenates, which have the capacity to transfer abnormal
α-synuclein to oligodendrocytes in addition to neurons, and to generate
oligodendroglioneural α-synucleinopathy (Watts et al., 2013; Prusiner et
al., 2015).
9.3. Tauopathies
Tauopathies are adult-age neurodegenerative diseases defined by the
accumulation of abnormally phosphorylated tau in neurons and glial
cells. Tau proteins are encoded by microtubule associated protein tau
gene, MAPT, the transcription of which by splicing produces six iso-
forms in the brain. Some tauopathies are identified as 4R-tauopathies,
and others as 3R-tauopathies depending on the axon 10 splicing. Spo-
radic tauopathies include Pick’s disease (PiD), a 3R tauopathy; and pro-
gressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and
argyrophilic grain disease (AGD), all of them 4R-tauopathies, each with
particular clinical, neuropathological and biochemical traits (Dickson
et al., 2011a, b; Muñoz et al., 2011; Tolnay and Braak, 2011; Lowe
and Kalaria, 2015; Kovacs, 2015; Kovacs and Tauopathies, 2015; Kovacs
et al., 2017). Familial tauopathies are linked to mutations in MAPT
and they are usually manifested neuropathologically as frontotempo-
ral lobar degeneration (FTLD) and clinically as dementia (FTD) with
parkinsonism; tau deposits are composed of 4R-, 3R- or 4R+3R-tau
repeats depending on the site of the mutation (Ghetti et al., 2011a, b).
Alzheimer’s disease (AD) has a component of neuronal tauopathy
but the presence of β-amyloid plaques is mandatory, at present, for
its categorization. Primary age-related tauopathy (PART) is a recently
named sporadic 4R+3R-tauopathy which is characterized by the pres-
ence of NFTs in the same localtions and with the same Braak stages
but without β-amyloid plaques (Crary et al., 2014; Jellinger et al.,
2015). Whether PART is part of AD is a matter of academic discussion
(Duyckaerts et al., 2015; Giaccone, 2015). Advanced stages of PART
may be causative of dementia with only tangles (Jellinger and Bancher,
1998). Aging-related tau astrogliopathy (ARTAG) is another 4R-tauopa-
thy in old age restricted to astrocytes (Kovacs et al., 2016). Globular
glial tauopathy will be defined later.
A combination of different tauopathies is not rare in old-aged indi-
viduals (Rahimi and Kovacs, 2014; Kovacs et al., 2017).
White matter atrophy, including demyelination and axonal loss, is
common in tauopathies (Chin and Goldman, 1996; Dickson et al., 1996).
Axonal damage in tauopathies is commonly interpreted as the result of
neuronal damage (Kneynsberg et al., 2017). However, glial cells may
act as additional pivotal players because of their damage resulting from
abnormal tau deposits in astrocytes and oligodendroglia.
Several types of inclusions in oligodendrocytes and oligodendroglial
processes are distinguished in tauopathies (Fig. 2). Coiled bodies and
threads are found in PiD, PSP, CBD and AGD (Wakabayashi et al.,
1994; Feany et al., 1995; Nishimura et al., 1995; Arima et al., 1997;
Tolnay et al., 1997; Ikeda et al., 1998; Jellinger, 1998; Komori, 1999;
Arai et al., 2001; Oyanagi et al.,
Fig. 2. Tau-immunoreactive oligodendroglial inclusions in tauopathies. A: progressive supranuclear palsy (PSP); B: corticobasal degeneration (CBD); C: argyrophilic grain disease (AGD);
D: frontotemporal lobar degeneration FTLD-tau (deln296); E: frontotemporal lobar degeneration FTLD-tau (P301 L); F: Pick’s disease (PiD). Paraffin sections, AT8 immunohistochemistry
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2001; Williams, 2006; Ferrer et al., 2008; Grinberg and Heinsen, 2009;
Mimuro et al., 2010; Pham et al., 2011; Kovacs et al., 2018; Komori,
2017). Similar inclusions are noted in the majority of cases with FTLD
linked to MAPT mutations (FTLD-tau) (Spillantini et al., 1997; Bird et
al., 1999; Iseki et al., 2001; Spina et al., 2008; Dickson et al., 2011a,
b; Ghetti et al., 2011a, 2011b). Coiled bodies also occur in dementia
pugilistica and chronic traumatic encephalopathy (Saing et al., 2012;
Ling et al., 2017), inflammatory diseases such as subacute sclerosis pa-
nencephalitis (Ikeda et al., 1995a, b), and LBDs (Dugger et al., 2014),
among other neurodegenerative disorders (Tacik et al., 2016).
Coiled bodies and interfascicular threads in PSP are composed of
abnormal tubules of 13 nm–15 nm in diameter and fuzzy outer con-
tours which are immunolabelled with anti-tau antibodies (Arima et al.,
1997). Oligodendroglial inclusions are fine and branching in PSP and
thick and comma-like in CBD (Komori, 1999; Arima, 2006; Williams,
2006). Differences in the morphology of abnormal tubules in oligoden-
droglial inclusions in tauopathies probably reflect differing molecular,
including tau, composition between these entities (Arima, 2006). Coiled
bodies are stained with antibodies against anti-phosphorylated tau anti-
bodies (Fig. 3), and antibodies against 4R-tau, but 3R-tau-immunoreac-
tive oligodendroglial inclusions are also recognized in PiD (Ferrer et al.,
2014).
Tau in coiled bodies is hyperphosphorylated at different sites includ-
ing Thr181, Ser199, Thr231, Ser262, Ser422, Ser202-Thr205 (antibody
AT8), Ser396-Ser404 (antibody PHF1) and Thr212/Ser214 (tau-100),
and has altered conformation as revealed by antibodies Alz50 (amino
acids 5–15) and MC-1 (amino acids 312–322); however, coiled bod-
ies are not stained with tau-C3 (which recognizes tau truncated at as-
partic acid 421) (Ferrer et al., 2014). Oligodendrocytes containing hy-
perphosphorylated tau inclusions coexpress phosphorylated (active) tau
kinases p-38, stress-activated kinase/c-Jun N-terminal kinase (SAPK/
JNK), mitogen-activated protein kinase/extracellular signal-regulated
kinase (MAPK/ERK) and glycogen synthase kinase-3 (Ferrer et al.,
2002, 2003a, c). PP2 A-like phosphatases probably modulate tau phos-
phorylation (Goldbaum and Richter-Landsberg, 2002).
In contrast to neurons with tangles in AD and tauopathies, the se-
quence encoded by exon 3 of the tau protein is under-expressed in oligo-
dendroglial coiled bodies in CBD but not in PSP (Feany et al., 1995;
Nishimura et al., 1997). Ubiquitin, apolipoprotein E, alpha1-antichy-
motrypsin and heparan sulfate are all absent from glial inclusions (Ikeda
et al., 1998).
Globular glial tauopathy (GGT) is a rare form of 4R-tauopathy with
predominant involvement of the white matter, and characterized by the
presence of globular inclusions in oligodendroglia and distinct tau-pos-
itive inclusions in astrocytes, in addition to deposition in neurons
(Molina et al., 1998; Bigio et al., 2001; Berry et al., 2001; Ferrer et al.,
2003b; Powers et al., 2003; Clark et al., 2015; Piao et al., 2005; Josephs
et al., 2006; Kovacs et al., 2008; Giaccone et al., 2008; Fu et al., 2010;
Ahmed et al., 2011; Graff-Radford et al, 2016) (Fig. 4). Neuropathologi-
cal consensus has classified GGT into three types: type I is usually man-
ifested as frontotemporal dementia and the principal involvement cor-
responds to the frontal and temporal lobes; type II is commonly man-
ifested by motor involvement and parkinsonism, and affects the cor-
ticospinal tracts; and type III presents with frontotemporal dementia,
parkinsonism and motor neuron disease, which implies a more general-
ized distribution of the tauopathy (Ahmed et al., 2013b). This schematic
classification has some affect on clinical practice (Burrell et al., 2016).
GGT is mostly sporadic but certain taoupathies linked to MAPT
mutations show variable amounts of globular inclusions in oligoden
drocytes and bizarre astrocytic inclusions resembling sporadic GGT
(Tacik et al., 2015; Zarranz et al., 2005, see also Ferrer et al., 2014;
Borrego-Écija et al., 2017). Tau phosphorylation sites and conforma-
tional modifications described in coiled bodies also occur in globular
inclusions in oligodendrocytes; in addition, globular inclusions contain
truncated forms of tau at the carboxy-terminal and are ubiquitinated
(Ferrer et al., 2014). Therefore, a major difference between coiled bod-
ies and globular glial inclusions is the stage of pre-tangle in the former
and the stage of tangle in the latter. Decreased nuclear TPPP/p25α par-
allels microglial activation, myelin loss and association with tau inclu-
sions in GGT (Rohan et al., 2016).
Small globular oligodendroglial inclusions (called small Pick bodies)
are seen in the white matter in PiD (Kovacs, 2015). Rare globular in-
clusions have been reported in a single case of familial AD (Gelpi et al.,
2013).
Protein aggregation in glial cells compromises stress responses and
protein degradation pathways. αB-crystallin and other small HSPs are
expressed in oligodendroglia (and astrocytes) in tauopathies. However,
they do not necessarily co-localize with tau inclusions, thus suggest-
ing generalized stress rather than restricted response in glial cells with
abnormal protein aggregates (López-González et al., 2014). It may be
posited that stress responses are directed to correcting protein misfold-
ing, and that, to a certain extent, they succeed, and aggregates are not
formed in many glial cells.
Ubiquitin-immunoreactivity is found in a minority of coiled bodies
but it is almost a constant in globular inclusions in GGT (Ferrer et al.,
2014). This might indicate variable involvement of the ubiquitin-pro-
teasome system in the development of oligodendroglial inclusions. Ad-
ditional information comes from cellular models in which proteasomal
inhibition in cultured oligodendrocytes leads to protein aggregate for-
mation (Leik et al., 2013). Histone deacetylase HDAC6 is expressed in
oligodendrocytes and its inhibition results in microtubule alteration,
and acetylation and phosphorylation of tau (Noack et al., 2014). Tau
acetylation inhibits its degradation and contributes to tau aggregation
(Min et al., 2010; Cohen et al., 2011). Accordingly, HDAC6 inhibition
induces tau acetylation, the formation of protein aggregates, the alter-
ation of stress responses and the impairment of autophagy (Leyk et al.,
2015).
A few glial cells colocalize with HSP and ubiquitin thus pinpoint-
ing the combined reaction of stress responses and impaired function of
the ubiquitin-protesome system (Richter-Landsberg and Bauer, 2004).
Further insights linking HDAC6, tau acetylation, tau phosphorylation,
stress responses, proteasome and autophagy are exemplified in oligo-
dendroglia cell culture paradigms (Richter-Landsberg, 2016).
Whether the constructs in cell cultures occur in all human
tauopathies deserves further research. Tau is acetylated in oligoden-
droglial inclusions in FTLD-tau (Irwin et al., 2013) but apparently not in
AGD including grains and coiled bodies (Grinberg et al., 2013). In this
way, factors coming into play in individual oligodendrocytes probably
have multiple facets in the different tauopathies.
Hyperphosphorylated tau intracytoplasmic filamentous inclusions
are commonly seen in transgenic mouse models of tauopathies both in
animals overexpressing human tau and those bearing different tau mu-
tations which are causative of familial FTLD-tau.
Tau pathology in glial cells has been generated in transgenic mice
overexpressing human tau in neurons and glial cells. In these ani-
mals, tau pathology resembling astrocytic plaques and coiled bodies
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Fig. 3. Double-labelling immunofluorescence and confocal microscopy to Olig2 (green) and AT8 (red) in several tauopathies: A: corticobasal degeneration (CBD); B, C: progressive
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Fig. 4. Tau-immunoreactive oligodendroglial inclusion (thin arrow) in globular glial
tauopathy (GGT). An astrocyte with hyper-phosphorylated tau deposits is labelled with a
thick arrow. Paraffin sections, AT8 immunohistochemistry slightlhy counterstained with
haematoxylin; bar = 25 μm.
are associated with glial and axonal degeneration (Higuchi et al., 2002).
Transgenic mice expressing G272 V tau accumulate abnormal fila-
ments in oligodendrocytes; these filaments are either straight or have a
twisted structure with a periodicity of 75 nm, and they are composed
of abnormal tau hyperphosphorylated at different sites. Fibrillar oligo-
dendroglial and neuronal inclusions are also seen in the spinal cord
(Götz et al., 2001). Transgenic mice bearing P301 L tau develop cyto-
plasmic neuronal inclusions, and oligodendroglial and astrocytic fila-
mentous inclusions composed of abnormal hyperphosphorylated tau ag-
gregates (Lin et al., 2003). Oligodendroglial inclusions are also seen in
transgenic mice bearing the P301S mutation (Fig. 5). Selective over-
expression of mutant tau in oligoden
drocytes using CNP promoter in mice produces filamentous inclusions
in oligodendrocytes and progressive impairment of axonal transport
followed by myelin and axonal disruption; these changes precede the
appearance of thioflavin-S-positive tau inclusions in oligodendrocytes
(Higuchi et al., 2005). Interstingly, endogenous mouse tau is deposited
in oligodendrocytes in mice expressing transgenic human tau, in a way
that makes evident that mouse tau has the capacity to be recruited and
aggregated in oligodendrocytes (Ren et al., 2014).
These models reveal that tau accumulation in oligodendroglial cells
is accompanied by axon degeneration and demyelination. White matter
damage is further demonstrated in the spinal cord of transgenic mice
bearing the P301 L tau mutation (Zher et al., 2004; Lin et al., 2005a,
b). Lesions are consistent with vacuolar myelopathy and dying-back ax-
onopathy; myelin debris is engulfed by macrophages whereas oligoden-
docytes in damaged regions have membrane-bound cytoplasmic inclu-
sions (Lin et al., 2005a, 2005b). Other studies stress the occurrence of
active caspase-3-immunoreactive, TUNEL-positive oligodendrocytes in
affected white matter, arguing that axonal degeneration is accompa-
nied by apoptosis of oligodendrocytes (Zher et al., 2004). Deleterious ef-
fects of abnormal tau in oligodendrocytes are further proven in cultured
oligodendrocytes in which the expression of human tau and FTDP-tau
mutant tau causes cell death (Richter-Landsberg, 2008).
Defective microtubule network and altered myelination in tau trans-
genic mice is associated with reduced expression of kinesin which mod-
ulates intracellular trafficking; abnormal tau may interfere with ki-
nesin-dependent MBP translocation thus favoring altered myelination in
these mice (Carson et al., 1997; Higuchi et al., 2002; Richter-Landsberg,
2008).
Curiously, neuronal expression of P301S tau accelerates OPC differ-
entiation and myelin formation following focal white matter demyelina-
tion (Ossola et al., 2016). Whether these changes move in favor of re-
generation is not known.
Fig. 5. Hyperphosphorylated tau accumulation in oligodendrocytes in P301S mice aged 8 months (thin arrows). A: hippocampus (one neuron containing tau is labelled with a thick
arrow); B: white matter of the somatosensory cortex. Double-labelling immunofluorescence and confocal microscopy to Olig2 (green) and AT8 (red); the figure on the right of the panel is
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Tau seeding in vivo has been demonstrated in a number of mouse
models after inoculation of human brain homogenates (Goedert et al.,
2017). Seeding and spreading of abnormal tau occurs after inoculation
of brain homogenates from AD and other tauopathies into the brain of
transgenic mice overexpressing human tau or mutated tau (Boluda et
al., 2015; Clavaguera et al., 2009, 2015; Lewis and Dickson, 2016). The
use of transgenic mice is based on the assumption that this substrate
facilitates tau seeding and propagation. The characteristics of seeding
differ depending on the type of tauopathy, implying that several types
of tau species have particular properties (Clavaguera et al., 2013a, b;
Boluda et al., 2015; Narasimhan et al., 2017). Seeding of human tau
from homogenates of AD and tauopathies with neuronal and glial com-
ponents is also observed after inoculation into the brain of wild-type
mice (Guo et al., 2016; Narasimhan et al., 2017). Tau-immunoreactive
oligodendroglial inclusions are observed after inoculation of CBD ho-
mogenates but apparently only very rarely or not at all following in-
oculation of AD homogenates (Boluda et al., 2015). All these exper-
iments have been performed using brain samples with tau pathology
only in neurons or in neurons and glial cells. Recent studies have shown
that sarkosyl-insoluble fractions of brain homogenates from ARTAG in-
oculated into the hippocampus of wild-type mice generate intracyto-
plasmic hyperphosphorylated tau inclusions in astrocytes, oligodendro-
cytes, fiber tracts and neurons near the site of injection (Ferrer et al.,
2018) (Fig. 6). These observations indicate that not only neurons but
also astrocytes containing hyperphosphorylated tau have the capability
of seeding tau to neurons and glial cells. Moreover, they point to the car-
dinal role of astrocytopathy in the pathogenesis of neurodegenerative
diseases with abnormal protein aggregates, including the participation
of oligodendrocyte targets in this process (Ferrer et al., 2018).
9.4. Alzheimer’s disease
Alzheimer’s disease (AD) is the most frequent cause of cognitive
decline and dementia in the elderly. Pathologically, AD is classically
defined by the combination of senile plaques composed of different
β-amyloid species, and neurons with neurofibrillary tangles (NFTs) con-
taining hyperphosphorylated 3R- and 4R-tau which disturbs micro-
tubule assembly, and results in the formation of paired helical fila-
ments. β-amyloid deposition also occurs in blood vessels, leading to
β-amyloid angiopathy, whereas abnormal tau is also accumulated in dy-
strophic neurites surrounding senile plaques and in neuropil threads
(Duyckaerts and Dickson, 2011; Lowe and Kalaria, 2015). NFTs progress
from the entorhinal and transentorhinal cortex to the hippocampus,
limbic system and cerebral cortex. NFTs also in
volve in parallel the olfactory bulb, selected nuclei of the brain stem, nu-
clei of the basal forebrain, amygdala and diencephalon. NFT progression
follows a sterotyped pattern which allows the categorization of sever-
ity into stages (Braak and Braak, 1991, 1999). β-amyloid deposition and
distribution of senile plaques also extends with disease progression but
the pattern differs from that of NFTs, at least in sporadic AD (Thal et al.,
2002). In addition to these basic alterations, AD exhibits a compendium
of biological alterations which modify many molecular pathways and
variegated functions (Ferrer, 2012; Braak and Del Tredici, 2015).
Reduced size of the white matter, white matter hyperlucencies and
myelin pallor are common abnormalities in AD (Barber et al., 1999;
Bartzokis et al., 2003; Gouw et al., 2008; Holland et al., 2008;
Radanovic et al., 2013; Amlien and Fjell, 2014; Firbank et al., 2016;
Joki et al., 2018). Changes in white matter are parallel but do not cor-
relate with β-amyloid deposition (Roseborough et al., 2017), and, im-
portantly, they are recognized at early stages of the disease (Hoy et al.,
2017). The size of the nuclei of oligodendrocytes is reduced in AD (Gagi
et al., 2012). In addition, several oligodendroglial nuclei in the white
matter show DNA oxidative damage, while other oligodendrocytes ex-
hibit increased expression of p53 as a marker of stress, and a senes-
cent phenotype (Al-Mashhadi et al., 2015; Wharton et al., 2015; Tse and
Herrup, 2017).
White matter radiological and neuropathological changes are accom-
panied by early and progressive reduction in the levels of cholesterol
and myelin proteins MBP, PLP and CNP (Vlkolinsky et al., 2001; Roher
et al., 2002), and decreased Olig2- and NG2-glia-immunoreactive cells
(Behrendt et al., 2013; Nielsen et al., 2013). The mechanisms of oligo-
dendroglial damage are not known, and several factors including in-
flammation, oxidative stress, apoptosis and tau deposition in neuronal
processes have been suggested (Cai and Xiao, 2016). in vitro studies
show the toxic effect of β-amyloid species on OPCs and oligodendro-
cytes (Xu et al., 2001; Takao et al., 2004; Desai et al., 2010). Activated
microglia induces death of OPCs and limits their function in remaining
cells (Pang et al, 2010). Curiously, Bridging interactor 1(BIN1), the sec-
ond most significant susceptibility locus in late-onset AD, is mainly ex-
pressed in mature oligodendrocytes and in white matter tracts (De Rossi
et al., 2016). Increased BIN1 expression and BIN1 interaction with tau
have been reported (Holler et al., 2014; Sottejeau et al., 2015); BIN1
also interacts with actin (Dräger et al., 2017), together pointing to pos-
sible BIN1-linked cytoskeletal alterations in oligodendocytes in AD.
Oligodendroglial cell death and myelin loss occur at early stages
in 3xTg-AD mice harbouring the human precursor amyloid protein
Swedish mutation, a presenilin knock-in mutation and P301 L tau. Ex-
posure to Aβ⁠1-42 increases caspase-3 expression and induces apo
Fig. 6. Hyperphosphorylated tau accumulation in two oligodendrocytes of the corpus callosum of wild-type mice aged ten months following hippocampal inoculation of sarkosyl-insoluble
fractions from pure Aging-related tau astrogliopathy (ARTAG) at the age of three months. Double-labelling immunofluorescence and confocal microscopy to Olig2 (green) and AT8 (red);











I. Ferrer Progress in Neurobiology xxx (2018) xxx-xxx
tosis of oligodendrocyte precursors in vitro that is reversed following vi-
ral vector-derived intracellular transport of an antibody against Aβ⁠1-42
(Desai et al., 2009, 2010).
These data must be interpreted with caution regarding white matter
changes in AD and their relation with altered oligodendrocytes. Vascu-
lar pathology, mostly affecting small blood vessels, is practically con-
stant in AD. In addition to β-amyloid angiopathy, atrophy, edema and
increased pynocitosis in endothelial cells, atrophy of the muscle cells,
thickening and disruption of the basal membrane and increased expres-
sion of collagen IV, heparan sulfate, proteoglycans and laminin are de-
tected in capillaries and arterioles. Moreover, aquaporin-4 expression is
altered in perivascular astrocytes (Kalaria et al., 1996; Ferrer, 2010).
These changes are consistent with chronic hypoperfusion (Kalback et al.,
2004).
Tau-immunoreactive inclusions in oligodendrocytes are not charac-
teristic of AD, although coiled bodies can be found in AD combined
with other tauopathies such as AGD. However, age-related increase in
β-amyloid plaques and β-amyloid angiopathy, tau-positive astrocytes
and oligodendrocytes (coiled bodies), and neuritic clusters occurs in
housed gorillas (Perez et al., 2013). Curiously, tauopathy but not β-amy-
loidopathy develops in wild mountain gorillas of similar age (Perez et
al., 2016). Intraneuronal and intraoligodendroglial tau accumulation oc-
curs in the temporal cortex in non-human primate cynomolgus mon-
key before the age of 20 months with poor correlation to the levels of
insoluble β-amyloid; AD-related pathology increases at more advanced
ages (Oikawa et al., 2010). Tau-immunoreactive oligodendroglial (and
neuronal and astrocytic) inclusions composed of straight filaments of
10–14 nm are also found in the brains of aged baboons (Schultz et al.,
2000). Available data are consistent with the idea that brain aging in
non-human primates is predominantly manifested as a tauopathy with
involvement of neurons and glial cells.
9.5. Amyotrophic lateral sclerosis and Frontotemporal lobar degeneration-
TDP (ALS/FTLD-TDP)
9.5.1. Amyotrophic lateral sclerosis (ALS)
ALS is a neurodegenerative disease involving the cortical motorneu-
rons, the motorneurons of the spinal cord and selected nuclei of the
brain stem, producing spasticity, muscle wasting, difficult swallowing
and final respiratory insufficiency. In addition to the motor system,
other regions can be affected; the frontal and temporal cortex is dam-
aged in some cases leading to cognitive impairment and dementia of
frontotemporal lobe type. Indeed, variable overlap exists between ALS
and FTLD (Hortobágyi and Cairns, 2015; Ince et al., 2015).
ALS can be classified as sporadic (sALS) or genetic (gALS), often
affecting several members of a family (fALS). The principal gene de-
fects causing adult fALS are mutations in SOD1 (superoxide dismutase
1), VAMP (vesicle associated membrane protein B and C), CHMP2B
(charged multivesicular body protein 2B), ANG (angiogenin), TARDBP
(transactive response (TAR) DNA binding protein of 43 kD: TDP-43),
FUS (fused-in-sarcoma), OPTN (optineurin), ATXN2 (ataxin 2), UBQLN
(ubiquilin 2), C9Orf72 (chromosome 9 open reading frame 72) and
SQTM1 (sequestosome 1 p62) (Hortobágyi and Cairns, 2015). Of these,
SOD1, CHMP2B, ANG, TARDBP, VCP, UBQLN, C9Orf72, FUS and
SQTM1 are also causative of FTLD (Hortobágyi and Cairns, 2015; Ince
et al., 2015). The majority of patients suffering from ALS are sporadic
with no known mutations; however, hexapeptide repeat expansions in
C9Orf72 are recognized in a number of apparently non-genetic ALS.
Loss of large motorneurons (Betz cells) in the motor cortex, de-
generation of the pyramidal tracts, loss of motorneurons in selected
nuclei of the brain stem and anterior horn of the spinal cord, and
myelin pallor of the corresponding optic nerves and anterior roots of the
spinal cord are the principal neuropathological characteristics of ALS.
Curiously, oculomotor nuclei in the brain stem and Onuf’s nuclei in
the lower spinal cord are spared in classical forms. Additonal involve-
ment of the Clarke’s column, posterior spinocerebellar tracts and pos-
terior tracts occurs in cases bearing SOD1 mutations. As indicated be-
fore, other regions of the brain, mainly the frontal and temporal cortex,
may be affected in some cases (Hortobágyi and Cairns, 2015; Ince et al.,
2015).
In addition to neuron loss, astrogliosis and microgliosis are accom-
panying reactions in the affected regions. Proximal axonal balloonings
filled with neurofilaments are rather common in rapidly progressing
cases. Remanining motorneurons show variable alterations including
disruption of the Golgi complex and intracytoplasmic inclusions which
have the morphology of skein-like inclusions, round inclusions and
small granular deposits, all of them containing abnormal TDP-43 (Ince
et al., 2015; Hortobágyi and Cairns, 2015). Bunina bodies composed of
cystatin C and transferrin are also concurrently observed. fALS due to
mutations in fused-sarcoma (FUS) do not contain these types of TDP-43
inclusions but rather round basophilic neuronal inclusions composed
of FUS, ubiquitin and p62 (Mackenzie and Neumann, 2017). There-
fore fALS-FUS cannot be considered within the spectrum of TDP-43 pro-
teinopathgies.
Staging of TDP-43 pathology in ALS has been proposed in line with
similar categorization stages in AD and PD (Brettschneider et al., 2013).
In stage 1, abnormal TDP-43 inclusions are restricted to motorneurons
of the primary motor cortex, motorneurons of the anterior horn of the
spinal cord and certain motor nuclei of the brain stem. In stage 2, abnor-
mal TDP-43 extends to neurons of the reticular formation of the brain
stem and deep nuclei of the cerebellum. In stage 3, TDP-43- immunore-
active inclusions are also noted in the prefrontal cortex and basal gan-
glia. In stage 4, the hippocampal formation and the anteromedial areas
of the temporal cortex show TDP-43-immunoreactive inclusions.
In a refinement of this staging proposal, posterior assessment iden-
tifies oligodendroglial TDP-43-immunoreactive inclusions as an early
pathological event in the spinal cord in ALS, and occasional involve-
ment of the oculomotor nucleus and sometimes the Onuf’s nucleus, at
advanced stages of the disease, categorized as stage 5 (Brettschneider et
al., 2014b)
9.5.2. Frontotemporal lobar degeneration-TDP
Frontotemporal lobar degeneration-TDP defines a subgroup of
non-tau FTLD cases with ubiquitin-immunoreactive inclusions whose
main component is abnormal TDP-43. About 50% are familial and
mainly linked to mutations in granulin (GRN), TARDBP, valosin (VAL)
and C9Orf72. Clinically, FTLD-TDP is manifested as behavioural vari-
ant, progressive non-fluent aphasia or semantic dementia. Pathologi-
cally, the frontal and temporal lobes are atrophic, while the cerebral
cortex in these regions shows neuron loss and spongiosis in the upper
cortical layers, and astrocytic gliosis; the white matter shows variable
reduction and myelin pallor. The hallmarks of FTLD-TDP are nuclear
TDP-43 mislocalization, neuronal intracytoplasmic and intranuclear in-
clusions, and aberrant neurites containing abnormal TDP-43. The major-
ity of tau-negative, TDP-43-negative FTLD cases with intracytoplasmic
inclusions contain FUS, and they are considered FUS-proteinopathies
(Neumann et al., 2009; Urwin et al., 2010).
Four FTLD-TDP neuropathological types have been proposed de-
pending on the amount and distribution of the types of inclusions
which roughly match with genetic variants (Mackenzie et al., 2009;
Mackenzie and Neumann, 2011; Bigio, 2011a; Cruts et al., 2013; Ash
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the cerebral neocortex and hippocampus, other brain regions are af-
fected, particularly the amygdala, striatum, thalamus, several nuclei
of the brain stem and motorneurons of the spinal cord. Characteris-
tic TDP-43-negative, p62- and ubiquitin-positive inclusions are noted in
the granular layer of the cerebellum in FTLD-TDP linked to C9Orf72
hexanucleotide repeat expansions (Simón-Sánchez et al., 2012). Further
molecular properties point to ALS/FTLD-TDP linked to C9Orf72 repeat
expansions as a particular type within TDP-43-proteinopathies (Bigio,
2011b, 2012).
Rather than a stage categorization, as applied in other neurodegen-
erative diseases, sequential distribution of TDP-43 pathology has been
proposed in FTLD-TDP (Brettschneider et al., 2014a). Pattern I (low-
est burden of pathology) is characterized by TDP-43 inclusions in the
orbital gyri, gyrus rectus and amygdala; pattern II affects the middle
frontal and anterior cingulated gyrus, anteromedial temporal lobe areas,
superior and medial temporal gyri, striatum, and red nucleus; stage III
involves the motor cortex, bulbar somatosensor neurons and the ante-
rior horn of the spinal cord; finally, pattern IV exhibits, in addition, in-
volvement of the visual cortex (Brettschneider et al., 2014a).
9.5.3. Common protein inclusions: common dysfunctions?
As mentioned above, neuronal intracytoplasmic TDP-43-immunore-
active inclusions are neuropathological hallmarks of the majority of
cases with ALS and, by definition, of all cases of FTLD-TDP (Arai et al.,
2006; Neumann et al., 2006). The presence of TDP-43 inclusions in hu-
man and transgenic mice bearing SOD1 mutations is controversial (Cai
et al., 2005; MacKenzie et al., 2007; Tan et al., 2007; Turner et al., 2008;
Shan et al., 2009; Maekawa et al., 2009; Okamoto et al., 2011).
TDP-43 in ALS/FTLD-TDP is abnormally phosphorylated (P-TDP43),
has abnormal solubility, presents truncated, pathogenic forms (Winton
et al., 2008; Zhang et al., 2009) and has characteristics of amyloid
(Bigio et al., 2013). This abnormal TDP-43 together with normal TDP-43
translocates from the nucleus to the cytoplasm giving rise to intracy-
toplasmic neuronal inclusions and aberrant neurites which are linked
to toxic effects on neurons (Hasegawa et al., 2008; Nishimura et al.,
2010; Barmada et al., 2010; Yang et al., 2010). Yet the effects of abnor-
mal TDP-43 are more complex, encompassing gain and loss of function
(Halliday et al., 2012). Altered proteasomal function and autophagy
play a role in the process of protein aggregation and deposition in af-
fected cells (Urushitani et al., 2010; Wang et al., 2010; van Eersel et
al., 2011; Barmada et al., 2014). Direct evidence of this involvement is
the immunoreactivity to ubiquitin and p62 of typical inclusions in ALS/
FTLD-TDP.
In addition to neuronal and neuritic TDP-43-positive inclusions,
oligodendroglial TDP-43-immunoreactive inclusions are found in the
anterior horn of the spinal cord in ALS (Brettschneider et al., 2013;
Rohan et al., 2014; Hortobágyi and Cairns, 2015) (Fig. 7). P-TDP-43-im-
munoreactive oligodendroglial inclusions in ALS are also encountered in
the motor, sensory and premotor cortex, but not in the corpus callosum,
cingulum or lateral tracts of the spinal cord (Fatima et al., 2015).
TDP-43 oligodendroglial pathology in the deep layers of the cere-
bral cortex and white matter is a characteristic feature in FTLD-TDP
(Neumann et al., 2007) (Fig. 8). It is more marked in frontal and tempo-
ral lobes but the brainstem and spinal cord are also affected (Neumann
et al., 2007).
Cerebral and cerebellar white matter damage when compared with
controls is observed in ALS cases bearing C9Orf72 repeat ex
Fig. 7. Phosphorylated TDP-43-immunoreactive oligodendroglial inclusions in the white matter of the lumbar spinal cord in amyotrophic lateral sclerosis (ALS). Paraffin sections; im-
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Fig. 8. TDP-43-immunoreactive oligodendroglial inclusions in the white matter in frontotemporal lobar degeneration-TDP43 (FTLD-TDP). A-C: linked to repeat expansions in C9Orf72;
D-F: sporadic cases with not known mutations. Paraffin sections; immunohistochemistry with anti-TDP-43 antibody, slightly counterstained with hematoxylin; bar = 25 μm.
pansions (Bede et al., 2013; Agosta et al., 2017). White matter involve-
ment is common in FTLD-TDP, and it is more marked in FTLD-TDP in
patients bearing GRN mutations when compared with patients bearing
C9Orf72 repeat expansions (Ameur et al., 2016; Papma et al., 2017;
Sudre et al., 2017).
Oligodendroglial cells have been implicated in the pathogenesis of
ALS in a cascade of effects which includes ROS production and damage,
recruitment of alterations derived from activated microglia and astro-
cytes, effects of toxic substances produced by damaged neurons and ab-
normal responses of NG2-glia (Ince et al., 2011; Nonneman et al., 2014).
However, most studies of this are based on SOD1 transgenic mice, which
are used as a model for a minority of cases with fALS responding to
unique pathogenic mechanisms not shared by other forms of familial
and sporadic ALS. Oligodendroglial SOD1 toxicity in transgenic mice
can barely be translated to sALS (Ferraiuolo et al., 2016). In the mouse
model of SOD1 mutation, altered oligodendrocytes appear in the grey
matter before disease onset and they increase with disease progression;
abnormal oligodendrocytes have reduced MBP and MCT1 expression,
thus resulting in altered myelin formation and impaired support to ax-
ons (Lee et al., 2012; Philips et al., 2013; Morrison et al., 2013).
MCT1 protein levels in motor cortex and MCT1 mRNA expression in
the spinal cord are also reduced in sALS (Lee et al., 2012): This is impor-
tant information, revealing altered oligodendroglial function in oligo-
dendrocytes in common forms of ALS. Moreover OPCs increase in num-
ber in motor cortex, but OPC differentiation is impaired and myelination
diminished, in transgenic mice and in human ALS (Kang et al., 2013).
Levels of oligodendrocytic connexin32 and connexin 47 are reduced
in the ventral horn of the spinal horn in SOD1-transgenic
mice, implying that oligo-astroglial interactions are disturbed in fALS
(Cui et al., 2014).
Prion-like spreading has been postulated in ALS (Polymenidou and
Cleveland, 2011; Kanouchi et al., 2012; Grad et al., 2015). The descrip-
tion of TDP-43 stages in ALS progression points to the likelihood of
abnormal TDP-43 spreading (Brettschneider et al., 2013). in vitro stud-
ies suggest the possibility of oligodendroglia involvement in the spread-
ing of TDP-43 pathology and subsequent neuronal degeneration in ALS.
In favor of this hypothesis is the observation of TDP-43 aggregates
in TDP-43-transfected neurons, astrocytes and oligodendrocytes under
conditions of proteasome inhibition; aggregates from dying cells are in-
corporated into neighbouring cells thus facilitating spreading of TDP-43
aggregates in vitro (Ishii et al., 2017). However, TDP-43 oligodendroglial
inclusions are not found in deep corticospinal and other white matter
tracts from the motor cortex, and as a consequence the propagation of
pathology between neurons may not involve oligodendrocytes (Fatima
et al., 2015).
FTLD-TDP linked to GRN mutations has a unique combination of
neuronal and glial inclusions. In addition to neuronal and glial
TDP-43-immunoreactive aggregates, other abnormal proteins are con-
sistently recognized in the cerebral cortex including 3R- and 4R-tau
neuronal pre-tangles and tau-immunoreactive astrocytes and oligoden-
drocytes, together with α-synuclein-positive oligodendroglial cells
(Hosokawa et al., 2017).
TDP-43 neuronal and oligodendroglial inclusions are also found in
the brains of AD and DLB but not in PD and tauopathies. TDP-43-im-
munoreactive neuronal inclusions predominate in the hippocampus and
amygdala where they rarely co-localize with neurofibrillary tangles
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α-synuclein and tau is seen in oligodendroglial cells (Higashi et al.,
2007).
9.6. Creutzfeldt-Jakob’s disease (CJD) and other prion diseases
Prion diseases or prionopathies are a group of transmissible en-
cephalopathies linked to the prion protein (PrP⁠C) which is converted
into an abnormally conformed protein named prion (PrP⁠SC). PrP⁠SC is
pathogenic and aggregates in brain and other tissues. Human prion
diseases are sporadic, iatrogenic or genetic Creutzfeld-Jakob’s disease
(CJD), Gerstmann-Straüsler-Scheinker (GSS) disease, and fatal familial
insomnia (FFI) due to mutations in PRNP gene. Animal prion diseases
are typical and atypical scrapie in sheep and goat, chronic wasting
disease in deer, elk, moose and reindeer, and bovine spongiform en-
cephlalopathy in cattle (Prusiner, 2004; Head et al., 2015).
Characteristic neuropathological lesions are neuron loss, spongiform
change (vacuolization of the neuropil due to extreme swelling of neu-
ronal processes), neuronal vacuolization and deposition of PrP⁠SC in the
neuropil forming synaptic-like inclusions, plaque-like, linear and per-
ineuronal deposits, and neuronal aggregates in some cases. This is ac-
companied by marked astrogliosis and reactive microgliosis (Gambetti
et al., 2011; Budka et al., 2011; Parchi et al., 2011; Ghetti et al., 2011a,
b; Head et al., 2015).
PrP⁠C is normally expressed not only in neurons but also in astro-
cytes and oligodendrocytes. PrP mRNA expression is similar in glial cells
and neurons and doubles during post-natal development in hamsters
and rats (Moser et al., 1995). Functions of PrP⁠C during development in-
clude modulation of the differentiation of human stem cells into neu-
rons, astrocytes and oligodendrocytes; silencing PrP surpresses differen-
tiation of OPCs into neurons, astrocytes and oligodendroglia (Leey and
Baskakov, 2014). This observation is in line with previous studies show-
ing that PrP⁠C during development and adulthood controls OPC prolif-
eration and oligodendroglial differentiation; PrP⁠C knock-out mice show
increased OPC proliferation, decreased oligodendroglial differentiation
and increased numbers of OPCs in adulthood without changes in myeli-
nation (Bribián et al., 2012). The effect of PrP upon stem/progenitor cell
signaling is through modulation of Notch (Martin-Lannere et al., 2017).
Little is known about the molecular pathology of oligodendrocytes
in prion diseases. Yet recent studies have shown preserved expression
of OLIG1, OLIG2, SOX10, NG2 and genes involved in myelination but
GALC (coding for galactosylceramidase), SLC2 A1 (solute carrier family
2 member 1: glucose transporter member 1: GLUT1) and MCT1 (mono-
carboxylic acid transporter 1) mRNA expression levels significantly re-
duced in the frontal cortex in CJD MM1 and CJD VV2 (Andrés-Benito et
al., 2018).
Prion diseases are the paradigm of transmissible neurodegenerative
disease in which the infectious agent is not a nucleic acid but a protein.
Prion protein (PrP⁠C), encoded by PRNP, is normal in the brain where it
has a number of physiological functions (Wulf et al., 2017). PrP⁠SC has
the same amino acid sequence as PRP⁠C (excepting in mutated forms due
to mutations in PRNP) but with abnormal conformation which confers
unique properties to the pathogenic protein, mainly resistance to sev-
eral physical and chemical agents, toxic effects on neurons, and, im-
portantly, the capacity to transmit the same abnormal conformation to
PRP⁠C under physical contact between PrP⁠SC and PrP⁠C (Prusiner, 1982;
Prusiner et al., 1998; Prusiner, 2004; Collinge and Clarke, 2007; Aguzzi
et al., 2008; Aguzzi and Falsig, 2012; Collinge, 2016). Recent studies
have shown that human astrocytes have the capacity to take up and
degrade normal and protease-resistant prion protein (Choi et al., 2014)
and that they can transfer PrP⁠SC to neurons via nanotubules (Victoria et
al., 2016) thereby contributing to prion disease progression.
Oligodendrocytes are apparently resistant to PrP⁠SC infectivity (Prinz
et al., 2004). However, axon and myelin damage in human, experimen-
tal scrapie and bovine spongiform encephalopathy is well documented
by optical and ultrastructural examination (Liberski et al., 1992). Ab-
normal interactions between oligodendroglia and astrocytes are ob-
served in experimental CJD and scrapie (Liberski et al., 1997), as is en-
gulfment of oligodendrocytes by hypertrophic astrocytes in the white
matter in CJD (Shintaku and Yutani, 2004). Moreover, PRP⁠SC is local-
ized as arrays adjacent to myelin fibers in the cerebrum and cerebellum
in CJD (El Hachimi et al., 1998). This is borne out by the observation of
PrP in the inner mesaxon and paranodal cytoplasm of oligodendroglia in
atypical (but not in classical) scrapie, thus supporting the idea that cer-
tain prion strains may interfere in trafficking between axons and oligo-
dendroglia (Jeffrey et al., 2017). Altered astrocyte/oligodendrocyte in-
teractions are probably important in the pathogenesis of CJD and other
glial prionopathies. The lack of information on this matter invites fur-
ther inquiry. Rarely, PrPRes can be seen in the nucleus and perinuclear
region in oligodendrocytes in CJD (Fernandez-Vega et al., 2018) (Fig.
9).
10. Final comments
There is extensive information about the structure and function of
oligodendrocytes, oligodendroglial precursors, diversity of precursors
and adult oligodendroglial cells, signaling pathways modulating mat-
uration and development of myelinating cells, interactions of oligo-
dendrocytes and neurons and astrocytes, and participation of oligo-
dendrocytes in energy metabolism, as well as mainte
Fig. 9. Double-labelling immunofluorescence and confocal microscopy with antibodies Olig2 (green) and SAF32 (red) in Creutzfeldt-Jakob disease (CJD) type VV2. Perinuclear PrP⁠SC
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nance of axon integrity and the normal functioning of the central ner-
vous system. Oligodendrocytes can be damaged following ischemia,
trauma, and inflammation of the central nervous system. The term
oligodendrogliopathy refers to the role of altered oligodendrocytes in
the pathogenesis of aging and certain neurological diseases. Oligoden-
drogliopathy has been recognized in neurodegenerative diseases with
abnormal protein aggregates in which abnormal proteins (i.e. α-synu-
clein, tau, TDP-43 and PrP) accumulate in the brain, including multi-
ple system atrophy, Lewy body diseases (such as Parkinson’s disease
and Dementia with Lewy bodies), sporadic and genetic tauopathies,
Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal lobar
degeneration linked to TDP43-proteinopathy, and Creutzfeldt-Jakob’s
disease. In most of these disorders, abnormal protein aggregates ac-
cumulate in oligodendrocytes (in addition to neurons and astrocytes).
Such deposits are not mere bystanders but rather are associated with
functional alterations in oligodendrocytes which impair myelination
and energy transfer to neurons and axons, and which disrupt the oligo-
dendrocyte/astrocyte syncytium that maintains homeostasis in the cen-
tral nervous system. Moreover, functional alterations in oligodendro-
cytes are also detected in the absence of oligodendroglial inclusions in
certain diseases. These aspects are emerging as cardinal factors in the
pathogenesis of neurodegenerative diseases with abnormal protein ag-
gregates. Despite recent advances, work is still needed to identify oligo-
dendroglial signaling pathways altered in neurodegenerative diseases
with abnormal protein aggregates, the regeneration capacities of oligo-
dendrocyte precursors, and the factors that can contribute to the restora-
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